Skip to main content
SpringerLink
Log in
Book cover

Hepatocellular Carcinoma pp 53–67Cite as

Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance

  • Chapter
  • First Online:

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

Abstract

Hepatocellular carcinoma (HCC) is responsible for more than 800,000 deaths globally. In the United States, HCC is the fastest growing cause of cancer deaths. Viral hepatitis is the leading cause of HCC, followed by alcoholic and nonalcoholic fatty liver disease. The contribution of nonalcoholic fatty liver disease to HCC incidence and mortality is expected to increase in future based on epidemiological and mathematical modeling studies. Routine HCC surveillance (or screening) is recommended in these high-risk groups, which can detect early-stage treatable cancers. Despite its important role in early HCC detection, adherence to surveillance remains low due to multiple provider- and patient-related issues. In order to increase the value of surveillance program to impact prognosis of future HCC cases, surveillance should be tailored according to the emerging risk factors to maximize its cost-effectiveness.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. https://doi.org/10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. World Cancer Report 2014. World Health Organization. 2014. Chapter 1.1. ISBN 9283204298.

    Google Scholar 

  3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73 e1. https://doi.org/10.1053/j.gastro.2011.12.061.

    Article  PubMed  Google Scholar 

  4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016. https://doi.org/10.1002/cncr.29936.

  6. Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11(5):472–7. https://doi.org/10.1016/j.cgh.2012.11.010.

    Article  PubMed  Google Scholar 

  7. van Meer S, de Man RA, Siersema PD, van Erpecum KJ. Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J Gastroenterol. 2013;19(40):6744–56. https://doi.org/10.3748/wjg.v19.i40.6744.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154(2):85–93. https://doi.org/10.7326/0003-4819-154-2-201101180-00006.

    Article  PubMed  Google Scholar 

  9. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology (Baltimore, Md). 2010;52(1):132–41. https://doi.org/10.1002/hep.23615.

    Article  Google Scholar 

  10. Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–91. https://doi.org/10.1001/jamaoncol.2017.3055.

    Article  PubMed Central  Google Scholar 

  11. Chhatwal J, Chen Q, Bethea E, Ladd M, Mueller P, Hutin Y, et al. Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs. Lancet Gastroenterol Hepatol. 2018;3(12):819. https://doi.org/10.1016/S2468-1253(18)30281-4.

    Article  PubMed  Google Scholar 

  12. Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29(6):919–28. https://doi.org/10.1016/j.bpg.2015.09.007.

    Article  PubMed  Google Scholar 

  13. Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86(7):1143–50.

    Article  CAS  PubMed  Google Scholar 

  14. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550–7.

    Article  PubMed  Google Scholar 

  15. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796–800.

    Article  CAS  PubMed  Google Scholar 

  16. Ang LW, Cutter J, James L, Goh KT. Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review. Vaccine. 2013;32(1):103–10. https://doi.org/10.1016/j.vaccine.2013.10.057.

    Article  PubMed  Google Scholar 

  17. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31. https://doi.org/10.1056/NEJMoa033364.

    Article  CAS  PubMed  Google Scholar 

  18. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29(3):971–5. https://doi.org/10.1002/hep.510290312.

    Article  CAS  PubMed  Google Scholar 

  19. Farrell GC, Wong VW-S, Chitturi S. NAFLD in Asia—as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10(5):307.

    Article  CAS  PubMed  Google Scholar 

  20. White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology. 2017;152(4):812–20. e5.

    Article  PubMed  Google Scholar 

  21. Singal AG, Murphy CC. Hepatocellular carcinoma: a roadmap to reduce incidence and future burden. J Natl Cancer Inst. 2018. https://doi.org/10.1093/jnci/djy184.

  22. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C in the United States: model-based predictions. Ann Intern Med. 2014;161(3):170–80. https://doi.org/10.7326/M14-0095.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology (Baltimore, Md). 2016;64(5):1442–50.

    Article  CAS  Google Scholar 

  24. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59(6):2188–95. https://doi.org/10.1002/hep.26986.

    Article  PubMed  Google Scholar 

  25. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56(6):1384–91. https://doi.org/10.1016/j.jhep.2011.10.027.

    Article  PubMed  Google Scholar 

  26. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology (Baltimore, Md). 2014;60(5):1767–75. https://doi.org/10.1002/hep.27222.

    Article  Google Scholar 

  27. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ. 2018;362:k2817. https://doi.org/10.1136/bmj.k2817.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21(Suppl 1):34–59. https://doi.org/10.1111/jvh.12248.

    Article  PubMed  Google Scholar 

  29. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–33. https://doi.org/10.1002/hep.29466.

    Article  CAS  PubMed  Google Scholar 

  30. Ganne-Carrie N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70(2):284–93. https://doi.org/10.1016/j.jhep.2018.10.008.

    Article  CAS  PubMed  Google Scholar 

  31. Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stal P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int. 2015;35(7):1862–71. https://doi.org/10.1111/liv.12764.

    Article  PubMed  Google Scholar 

  32. Schutte K, Bornschein J, Kahl S, Seidensticker R, Arend J, Ricke J, et al. Delayed diagnosis of HCC with chronic alcoholic liver disease. Liver Cancer. 2012;1(3–4):257–66. https://doi.org/10.1159/000343840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, Giannini E, et al. Comparison between alcohol-and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2016;43(3):385–99.

    Article  CAS  PubMed  Google Scholar 

  34. Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila). 2012;5(9):1124–30. https://doi.org/10.1158/1940-6207.CAPR-12-0046.

    Article  Google Scholar 

  35. Trevisani F, Magini G, Santi V, Morselli-Labate AM, Cantarini MC, Di Nolfo MA, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007;102(5):1022–31. https://doi.org/10.1111/j.1572-0241.2007.01100.x.

    Article  PubMed  Google Scholar 

  36. Costentin CE, Mourad A, Lahmek P, Causse X, Pariente A, Hagege H, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study. Cancer. 2018;124(9):1964–72. https://doi.org/10.1002/cncr.31215.

    Article  PubMed  Google Scholar 

  37. Guirguis J, Chhatwal J, Dasarathy J, Rivas J, McMichael D, Nagy LE, et al. Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States. Alcohol Clin Exp Res. 2015;39(11):2085–94. https://doi.org/10.1111/acer.12887.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md). 2011;53(3):1020–2. https://doi.org/10.1002/hep.24199.

    Article  Google Scholar 

  39. Llovet JM, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, Greten TF, Raymond E, Roskams T, De Baere T, Ducreux M, Mazzaferro V, Bernardi M, Bruix J, Colombo M, Zhu A. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.

    Article  Google Scholar 

  40. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74. https://doi.org/10.1007/s12072-010-9165-7.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kansagara D, Papak J, Pasha AS, O’Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014;161(4):261–9. https://doi.org/10.7326/M14-0558.

    Article  PubMed  Google Scholar 

  42. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417–22. https://doi.org/10.1007/s00432-004-0552-0.

    Article  PubMed  Google Scholar 

  43. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10(4):204–9. https://doi.org/10.1258/096914103771773320.

    Article  PubMed  Google Scholar 

  44. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (Baltimore, Md). 2011;54(6):1998–2004. https://doi.org/10.1002/hep.24581.

    Article  Google Scholar 

  45. Kanwal F, El-Serag HB, Ross D. Surveillance for hepatocellular carcinoma: can we focus on the mission? Clin Gastroenterol Hepatol. 2015;13(4):805–7. https://doi.org/10.1016/j.cgh.2014.12.016.

    Article  PubMed  Google Scholar 

  46. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. https://doi.org/10.1371/journal.pmed.1001624.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168(1):98–104. https://doi.org/10.1093/aje/kwn120.

    Article  PubMed  Google Scholar 

  48. Cucchetti A, Garuti F, Pinna AD, Trevisani F. Length time bias in surveillance for hepatocellular carcinoma diagnosis and how to avoid it. Hepatol Res. 2016. https://doi.org/10.1111/hepr.12672.

  49. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005. https://doi.org/10.1056/NEJMoa1206809.

    Article  CAS  PubMed  Google Scholar 

  50. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981–90.

    Article  PubMed  Google Scholar 

  51. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, et al. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108(3):416–24. https://doi.org/10.1038/ajg.2012.445.

    Article  PubMed  Google Scholar 

  52. McMahon B, Block J, Block T, Cohen C, Evans AA, Hosangadi A, et al. Hepatitis-associated liver cancer: gaps and opportunities to improve care. J Natl Cancer Inst. 2016;108(4). https://doi.org/10.1093/jnci/djv359.

  53. Zaman SN, Johnson PJ, Williams R. Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. Cancer. 1990;65(7):1607–10.

    Article  CAS  PubMed  Google Scholar 

  54. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virologic response in veterans with HCV-infection. Hepatology (Baltimore, Md). 2016;64:130–7. https://doi.org/10.1002/hep.28535.

    Article  CAS  Google Scholar 

  55. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136(1):138–48.

    Article  CAS  PubMed  Google Scholar 

  56. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol. 1996;105(1):65–75.

    Article  CAS  PubMed  Google Scholar 

  57. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology. 2002;222(1):89–94. https://doi.org/10.1148/radiol.2221010767.

    Article  PubMed  Google Scholar 

  58. Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: is one-size-fits-all strategy outdated? Curr Hepatol Rep. 2017;16(1):64–71. https://doi.org/10.1007/s11901-017-0336-z.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011;141(1):141–9. https://doi.org/10.1053/j.gastro.2011.03.045.

    Article  CAS  PubMed  Google Scholar 

  60. Wang Y, Luo Q, Li Y, Deng S, Wei S, Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One. 2014;9(1):e84484. https://doi.org/10.1371/journal.pone.0084484.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.

    Article  CAS  PubMed  Google Scholar 

  62. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.

    Article  CAS  PubMed  Google Scholar 

  63. Kudo M. Regorafenib as second-line systemic therapy may change the treatment strategy and management paradigm for hepatocellular carcinoma. Liver Cancer. 2016;5(4):235–44. https://doi.org/10.1159/000449335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8(10):877–83. https://doi.org/10.1016/j.cgh.2010.03.025.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Tobkes AI, Nord HJ. Liver biopsy: review of methodology and complications. Dig Dis (Basel, Switzerland). 1995;13(5):267–74.

    Article  CAS  Google Scholar 

  66. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;156(5):387–9. https://doi.org/10.7326/0003-4819-156-5-201203060-00012.

    Article  PubMed  Google Scholar 

  67. Sherman M. Whither hepatocellular carcinoma screening? Hepatology (Baltimore, Md). 2012;56(6):2412–4. https://doi.org/10.1002/hep.26138.

    Article  Google Scholar 

  68. Chirovsky D, Lich KH, Barritt AS. Screening for hepatocellular carcinoma in chronic liver disease. Ann Intern Med. 2015;162(3):238–9. https://doi.org/10.7326/l15-5049.

    Article  PubMed  Google Scholar 

  69. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738–47. https://doi.org/10.7326/0003-4819-151-10-200911170-00010. 151/10/738 [pii].

    Article  PubMed  PubMed Central  Google Scholar 

  70. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst. 2010;102(16):1238–52. https://doi.org/10.1093/jnci/djq242. djq242 [pii].

    Article  PubMed  PubMed Central  Google Scholar 

  71. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med. 2010;153(6):368–77. https://doi.org/10.7326/0003-4819-153-6-201009210-00004.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Kulasingam SL, Havrilesky LJ, Ghebre R, Myers ER. Screening for cervical cancer: a modeling study for the US Preventive Services Task Force. J Low Genit Tract Dis. 2013;17(2):193–202. https://doi.org/10.1097/LGT.0b013e3182616241.

    Article  PubMed  PubMed Central  Google Scholar 

  73. de Koning HJ, Meza R, Plevritis SK, Ten Haaf K, Munshi VN, Jeon J, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2013. https://doi.org/10.7326/M13-2316. 1809424 [pii].

  74. Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017;8(6):e101. https://doi.org/10.1038/ctg.2017.26.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med. 2012;156(12):841–7. https://doi.org/10.7326/0003-4819-156-12-201206190-00004.

    Article  PubMed  Google Scholar 

  76. D’Ambrosio R, Colombo M. Should surveillance for liver cancer be modified in hepatitis c patients after treatment-related cirrhosis regression? Liver Int. 2016. https://doi.org/10.1111/liv.13106.

  77. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342–59.e2. https://doi.org/10.1016/j.cgh.2012.10.001.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124–31 e1. https://doi.org/10.1016/j.cgh.2015.07.019.

    Article  CAS  PubMed  Google Scholar 

  79. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology (Baltimore, Md). 2010;51(2):595–602. https://doi.org/10.1002/hep.23314.

    Article  Google Scholar 

  80. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49(4):608–12. https://doi.org/10.1016/j.jhep.2008.06.018.

    Article  PubMed  Google Scholar 

  81. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–8. https://doi.org/10.1016/j.cgh.2008.11.005.

    Article  PubMed  Google Scholar 

  82. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (Baltimore, Md). 2006;44(4):865–73. https://doi.org/10.1002/hep.21327.

    Article  CAS  Google Scholar 

  83. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50. https://doi.org/10.1056/NEJMra0912063.

    Article  CAS  PubMed  Google Scholar 

  84. Yeh MM, Daniel HD, Torbenson M. Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol. 2010;23(2):276–83. https://doi.org/10.1038/modpathol.2009.174.

    Article  CAS  PubMed  Google Scholar 

  85. Vandenbulcke H, Moreno C, Colle I, Knebel JF, Francque S, Serste T, et al. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: a prospective study. J Hepatol. 2016;65(3):543–51. https://doi.org/10.1016/j.jhep.2016.04.031.

    Article  CAS  PubMed  Google Scholar 

  86. Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol: WJG. 2009;15(28):3462–71. https://doi.org/10.3748/wjg.15.3462.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Lin C-W, Lin C-C, Mo L-R, Chang C-Y, Perng D-S, Hsu C-C, et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol. 2013;58(4):730–5. https://doi.org/10.1016/j.jhep.2012.11.045.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Yueran Zhuo & Jagpreet Chhatwal

  2. Harold and Inge Marcus Department of Industrial and Manufacturing Engineering, Pennsylvania State University, University Park, PA, USA

    Qiushi Chen

Authors
  1. Yueran Zhuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiushi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jagpreet Chhatwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jagpreet Chhatwal .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Yujin Hoshida

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zhuo, Y., Chen, Q., Chhatwal, J. (2019). Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance. In: Hoshida, Y. (eds) Hepatocellular Carcinoma. Molecular and Translational Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-21540-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-21540-8_3

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-21539-2

  • Online ISBN: 978-3-030-21540-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation